Autozone Inc
Change company Symbol lookup
Select an option...
AZO Autozone Inc
LVGO Livongo Health Inc
SJMiv.P Invesco BulletShares 2022 Hi Yld Corp Bd ETF
INTC Intel Corp
AAPL Apple Inc
VAL Valaris PLC
GE General Electric Co
XOM Exxon Mobil Corp
MSFT Microsoft Corp
AMZN Amazon.com Inc
Go

Consumer Discretionary : Specialty Retail | Large Cap BlendCompany profile

AutoZone, Inc. is a retailer and distributor of automotive replacement parts and accessories in the United States. The Company operates through the Auto Parts Locations segment. The Auto Parts Locations segment is a retailer and distributor of automotive parts and accessories. As of February 10, 2018, the Company operated through 6,088 locations in the United States, Puerto Rico, Mexico and Brazil. The Company's stores carry product lines for cars, sport utility vehicles, vans and light trucks, including new and remanufactured automotive hard parts, maintenance items, accessories and non-automotive products. The Company's other operating segments include ALLDATA, which produces, sells and maintains diagnostic and repair information software used in the automotive repair industry, and E-commerce, which includes direct sales to customers through www.autozone.com.

Closing Price
$1,169.00
Day's Change
-3.66 (-0.31%)
Bid
--
Ask
--
B/A Size
--
Day's High
1,186.36
Day's Low
1,167.47
Volume
(Heavy Day)
Volume:
263,125

10-day average volume:
202,854
263,125

American College of Radiology, Breast Cancer Research Foundation and GE Healthcare Announce a Planned Trial to Evaluate Use of Contrast Enhanced Mammography for Screening Women with Dense Breasts

7:30 am ET December 2, 2019 (PR Newswire) Print

In a new effort to improve early breast cancer detection and reduce false positive exams in women with dense breasts, the American College of Radiology (ACR), Breast Cancer Research Foundation (BCRF) and GE Healthcare are partnering to support the Contrast Enhanced Mammography Imaging Screening Trial (CMIST).

https://mma.prnewswire.com/media/1037830/contrast_enhanced_spectral_mammography.jpg

The planned trial, managed by the ACR Center for Research and Innovation, seeks to determine if contrast enhanced spectral mammography (CESM) screening provides more accurate cancer detection compared to combination of digital breast tomosynthesis (DBT) and whole breast ultrasound (WBUS) in women with dense breasts.

Approximately 40 percent of women age 40 and over have dense breasts, which can make detection of breast cancer more challenging using mammography alone. With wider digital breast tomosynthesis (DBT) adoption, and increased use of supplemental screening ultrasound due to breast density notification laws, many women with dense breasts are screened each year with both DBT and whole breast ultrasound (WBUS).

"CMIST will investigate the challenges of current screening options for women with dense breasts," said Dorraya El-Ashry, PhD, BCRF Chief Scientific Officer. "The goal is to reduce false positive rates while improving breast cancer detection. Early detection remains key to improving breast cancer outcomes and our collective goal is to optimize critical tools for diagnosis."

CESM combines mammography and vascular-based screening methods that may offer a more efficient screening approach. CESM highlights areas of unusual blood flow patterns in a simple and quick procedure. Early studies of CESM in screening women with dense breasts have shown that CESM has the potential to increase the breast cancer detection rate by 70-80% compared to conventional mammography.1

Expected to launch in spring 2020, the paired-design multicenter trial will evaluate the performance of CESM in screening women with mammographically dense breasts (BI-RADS density categories c and d), ages 40-75, at average-to-intermediate risk for breast cancer, compared to the combination of tomosynthesis and ultrasound.

"The new CMIST Trial can help determine if CESM can provide a more accurate and efficient screening approach for women with dense breasts," said CMIST Principal Investigator Christopher Comstock, MD, FACR, FSBI, director of breast imaging clinical trials, Memorial Sloan Kettering Cancer Center.

"We know that one size does not fit all when it comes to breast care, and that it's critical to offer a personalized approach to breast cancer screening," says Agnes Berzsenyi, President and CEO of Women's Health at GE Healthcare. "We're excited to support this important study to further evaluate the clinical benefits of CESM so that clinicians can be even more confident in their diagnosis and quickly get answers for their patients."

About the American College of RadiologyThe American College of Radiology is a membership organization of 39,000 radiologists, radiation oncologists and medical physicists dedicated to serving patients and society by empowering radiology professionals to advance the practice, science and professions of radiological care.

About BCRFThe Breast Cancer Research Foundation (BCRF) is dedicated to ending breast cancer by advancing the world's most promising research. Founded by Evelyn H. Lauder in 1993, BCRF-funded investigators have been deeply involved in every major breakthrough in breast cancer prevention, diagnosis, treatment, survivorship and metastasis. BCRF is the largest private funder of breast cancer research worldwide.

About GE HealthcareGE Healthcare is the $19.8 billion healthcare business of GE (NYSE: GE). As a leading provider of medical imaging, monitoring, biomanufacturing, and cell and gene therapy technologies, GE Healthcare enables precision health in diagnostics, therapeutics and monitoring through intelligent devices, data analytics, applications and services. With over 100 years of experience in the healthcare industry and more than 50,000 employees globally, the company helps improve outcomes more efficiently for patients, healthcare providers, researchers and life sciences companies around the world. Follow us on Facebook, LinkedIn, Twitter and The Pulse for latest news, or visit our website https://corporate.gehealthcare.com/ for more information.

1 Sung et al. Radiology Oct 2019

https://c212.net/c/img/favicon.png?sn=DC53292&sd=2019-12-02

View original content to download multimedia:http://www.prnewswire.com/news-releases/american-college-of-radiology-breast-cancer-research-foundation-and-ge-healthcare-announce-a-planned-trial-to-evaluate-use-of-contrast-enhanced-mammography-for-screening-women-with-dense-breasts-300967194.html

SOURCE American College of Radiology

https://rt.prnewswire.com/rt.gif?NewsItemId=DC53292&Transmission_Id=201912020730PR_NEWS_USPR_____DC53292&DateId=20191202

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.